# ClinicalIntelPulse Deal Signal — M&A & Licensing Intelligence for Clinical Assets

> ClinicalIntelPulse Deal Signal — M&A & Licensing Intelligence for Clinical Assets is a paid API for AI agents from clinicalintelpulse.vercel.app, paid per call via x402, $0.35/call, status unknown (last checked 2026-09-15).

Returns M&A and licensing deal signals for Phase 2/3 clinical assets, including acquisition probability scores, deal comps, and transaction multiples for a given disease or asset.

## Facts

- Endpoint: GET https://clinicalintelpulse.vercel.app/api/clinical/deal-signal
- Price: $0.35/call
- Payment: x402
- Status: unknown
- Last checked: 2026-09-15
- Activations on Zero: 0
- Tags: x402
- Canonical page: https://www.zero.xyz/c/clinicalintelpulse-deal-signal-m-a-licensing-intelligence-for-b307d08c
- Structured record (JSON): https://api.zero.xyz/v1/capabilities/cap_FtAhKH2KBctgtWLJ2BQXO

Status and success rate cover calls made through Zero and Zero's own probes. Third-party monitors may report differently.

## How to call it through Zero

Zero handles the 402 payment challenge and records the run. With the Zero CLI installed (`npm i -g @zeroxyz/cli`):

```sh
zero fetch --capability clinicalintelpulse-deal-signal-m-a-licensing-intelligence-for-b307d08c
```

Example prompt: Pull the deal signals for Phase 2/3 oncology assets right now — I want to see which ones are most likely to get acquired or licensed, along with transaction multiples and recent deal comps.

## When to prefer this

Use this endpoint when an agent needs to identify acquisition or licensing targets among clinical-stage biotech assets, assess deal probability for specific disease areas, or benchmark transaction multiples against historical comps. Prefer this over general pipeline endpoints when the primary goal is business development intelligence or biotech investment screening rather than clinical or scientific analysis.

## Known failure modes

- Disease area or therapeutic category not recognized — returns empty result or 400 error
- No active Phase 2/3 assets found for the queried indication — returns empty deal signal list
- Payment not processed (x402) — returns 402 Payment Required before data is delivered
- Stale deal comps if underlying transaction database has not been recently updated
- Rate limiting if too many calls made in short succession

## How this service works

Biotech M&A + licensing deal signal for clinical-stage drugs — Phase 2/3 assets most likely to be acquired or licensed, with acquisition targets, deal comps, transaction multiples and estimated deal values. Worldwide. For biotech-investing and BD agents.

## Output

A ranked list of Phase 2/3 clinical assets with M&A and licensing probability scores, relevant deal comparables (similar past transactions), and transaction multiples — giving BD and investing agents a structured view of which assets are most likely to attract acquisition or licensing activity.

## Request schema (JSON Schema)

```json
{
 "type": "object",
 "$schema": "https://json-schema.org/draft/2020-12/schema",
 "required": [
  "input"
 ],
 "properties": {
  "input": {
   "type": "object",
   "required": [
    "type",
    "method"
   ],
   "properties": {
    "type": {
     "type": "string",
     "const": "http"
    },
    "method": {
     "enum": [
      "GET",
      "HEAD",
      "DELETE"
     ],
     "type": "string"
    },
    "queryParams": {
     "type": "object",
     "properties": {
      "lang": {
       "type": "string"
      },
      "stage": {
       "type": "string"
      },
      "condition": {
       "type": "string"
      },
      "deal_type": {
       "type": "string"
      }
     }
    }
   },
   "additionalProperties": false
  },
  "output": {
   "type": "object",
   "required": [
    "type"
   ],
   "properties": {
    "type": {
     "type": "string"
    },
    "errors": {
     "type": "object",
     "description": "Documented error responses, keyed by HTTP status code",
     "additionalProperties": {
      "type": "object",
      "required": [
       "description"
      ],
      "properties": {
       "example": {
        "type": "object"
       },
       "description": {
        "type": "string"
       }
      }
     }
    },
    "example": {
     "type": "object"
    }
   }
  }
 }
}
```

## Response schema (JSON Schema)

```json
{
 "type": "json",
 "example": {
  "query_summary": {
   "as_of": "2026-06-07",
   "stage": "both",
   "condition": "Obesity",
   "deal_type": "both"
  },
  "market_context": {
   "approved_leaders": [
    "Semaglutide (Novo Nordisk — Wegovy)",
    "Tirzepatide (Lilly — Zepbound)"
   ],
   "big_pharma_strategic_need": "Roche, AstraZeneca, Pfizer, Amgen all need next-gen obesity assets. Roche acquired Carmot Therapeutics for $2.7B. AZ acquired Eccogene for obesity pipeline.",
   "total_addressable_market_usd_bn": 100
  },
  "recent_deal_comps": [
   {
    "deal": "Roche / Carmot Therapeutics",
    "year": 2023,
    "stage": "PHASE1/2",
    "mechanism": "GLP-1 peptide",
    "value_usd_bn": 2.7
   },
   {
    "deal": "AstraZeneca / Eccogene",
    "year": 2024,
    "stage": "PHASE2",
    "mechanism": "Small-molecule GLP-1",
    "value_usd_bn": 1.85
   },
   {
    "deal": "Amgen / ChemoCentryx",
    "year": 2022,
    "stage": "Approved",
    "mechanism": "C5aR1",
    "value_usd_bn": 3.7
   }
  ],
  "acquisition_targets": [
   {
    "asset": "Mazdutide (IBI362)",
    "risks": [
     "China geopolitical risk for IP transfer",
     "Phase 3 US/EU data needed before deal close"
    ],
    "stage": "PHASE3",
    "company": "Innovent Biologics (China)",
    "deal_comp": "Structure Day1 Biosciences (Pfizer) $1.25B + milestones — Phase 2 obesity asset. Mazdutide later-stage = premium.",
    "mechanism": "GLP-1/glucagon dual agonist",
    "probability": "High",
    "clinical_data": "Phase 3 China data strong — 14.5% body weight reduction at 52 weeks",
    "deal_rationale": "Ex-China rights available. Differentiated vs. semaglutide on muscle preservation. Lilly or Roche most likely acquirers.",
    "estimated_deal_value_usd_m": "800-2000"
   }
  ],
  "deal_timing_signals": "Obesity M&A is peak hot. Big pharma BD teams are actively searching — any Phase 2 readout with >10% weight loss and clean safety profile will attract inbound interest within 3-6 months of data release.",
  "licensing_opportunities": [
   {
    "asset": "CT-388 (dual GLP-1/GIP)",
    "notes": "Roche may sublicense ex-US rights to regional partners in Asia/LatAm",
    "company": "Carmot Therapeutics (acq. Roche)",
    "estimated_license_value_usd_m": "300-800"
   }
  ]
 }
}
```

## More

- Live health (JSON, refreshed every minute): https://www.zero.xyz/c/clinicalintelpulse-deal-signal-m-a-licensing-intelligence-for-b307d08c/health.json
- [Zero catalog index](https://www.zero.xyz/llms.txt)
- [Other services from clinicalintelpulse.vercel.app](https://www.zero.xyz/host/clinicalintelpulse.vercel.app/llms.txt)